Compulsory licensing of covid-19 treatments unlikely in China, Japan and South Korea
He Jing, Lu Yong,
Essenese Obhan, Nick Redfearn , Lisa Yong , Toyotaka Abe , Jeong Yeol Choe , Kyung Ae Yoon , Cho Rong Yun and Son Jin
12 August 2020
Experts consulted by IAM in the three countries downplay interventions, but it may be a different story in Indonesia and India
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now
Already have access? Login below
He Jing
View full biography
Author | Founder
[email protected]
GEN Law & Consulting
Lu Yong
Author | Senior counsel
GEN Law & Consulting
Essenese Obhan
View full biography
Author | Founding partner
Obhan & Associates
Nick Redfearn
Author | Principal, Global Head of Enforcement
Rouse
Lisa Yong
Author | Principal
Rouse
Toyotaka Abe
Author | Partner
TMI Associates
Jeong Yeol Choe
Author | Partner
Yulchon LLC
Kyung Ae Yoon
Author | Senior patent attorney
Yulchon LLC
Cho Rong Yun
Author | Associate
Yulchon LLC
Son Jin
Author | Foreign attorney
Yulchon LLC